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Abstract
Background: Patients with gastric cancer in China have worse outcome and poorer prognosis. Tumor-induced
lymphangiogenesis plays a crucial role in metastasis and tumor progression. The intratumoral and peritumoral
lymphatics were supposed to have different biological effects. Three major growth factors, vascular endothelial
growth factor- (VEGF)-A, VEGF-C and VEGF-D, are involved in the activation process via their receptors (VEGFRs).
The purpose of current study is to investigate the significant difference between intratumoral and peritumoral
lymphatic vessel density (LVD) in gastric cancer and their correlations with lymphangiogenetic growth factors.
Methods: Intratumoral LVD (I-LVD) and peritumoral LVD (P-LVD) of 123 patients with primary gastric cancer were
assessed after staining with D2-40, and confirmed by double staining with D2-40/CD34. Proliferative activity of
lymphatics endothelium was evaluated by double staining with D2-40/Ki-67. The associations were analyzed
between I-LVD/P-LVD and the expression level of VEGF-A, VEGF-C, VEGF-D and the receptor VEGFR-3, which was
measured by immunohistochemistry (IHC). The correlations of I-LVD and P-LVD with patient prognosis were also
valued.
Results: (1) The peritumoral lymphatics (PTLs) were relatively enlarged with dilated lumen compared with the
intratumoral lymphatics (ITLs). Increased P-LVD was significantly higher than I-LVD (P < 0.05). (2) P-LVD was found
significantly associated with lymph node metastasis (LNM) (P < 0.001), lymphatic vessel invasion (LVI) (P < 0.001),
VEGF-C (P = 0.003), VEGF-D expression level (P = 0.005) and VEGFR-3 expression level (P < 0.001) in peritumoral
tissues, despite no significant association was found between above variants with I-LVD. However, increased I-LVD
was demonstrated to be associated with decreased tumor volume (P < 0.001). Neither I-LVD nor P-LVD was
correlated with VEGF-A expression (P > 0.05). (3) Proliferative activity of lymphatics endothelium was observed in
PTLs, in spite of ITLs. (4) Increased P-LVD, but not I-LVD, was indicated to be an independent risk factor for lymph
node metastasis by multivariate logistic regression analysis, and was related to worse disease-free survival and
overall survival.
Conclusions: PTLs play roles in gastric cancer progression. Increased P-LVD, but not I-LVD, was significantly
associated with VEGF-C/-D/VEGFR-3 system, and could be an independent risk factor for lymph node metastasis
and a prognostic factor in gastric cancer.
Background
Gastric cancer is the main leading cause of cancer-
related death in China. About 80% ~ 90% patients are
diagnosed at advanced stage with poor outcome, com-
monly with lymphatic dissemination and distant
metastasis. During the past several years, tumor-induced
lymphangiogenesis driven by lymphangiogenic growth
factors has been firmly established as a novel mechan-
ism for cancer progression. Nowadays, an increasing
number of experts believe that intratumoral lymphatics
(ITLs, the lymphtics within the tumors) and peritumoral
lymphatics (PTLs, lymphtics at the periphery) play
exactly distinct biological roles on tumor behavior and
prognosis in different types of tumors. In gastric cancer,
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I-LVD had the higher presence of lymph node metasta-
sis in early stage [1], while P-LVD could be an indepen-
dent risk factor for lymph node metastasis and
prognosis [2]. However, function of I-LVD and P-LVD
and their correlations with VEGFs expression haven’t
been clarified yet.
A number of studies have demonstrated the crucial
roles of VEGFs expressions on tumor progression and
prognosis in gastric cancer. VEGF-C and VEGF-D, two
members of VEGF family, have been defined as the lym-
phangiogenic growth factors and play an important role
in tumor lymphangiogenesis via activation of VEGFR-3,
which is mainly expressed in lymphatic endothelial cells
(LECs). VEGF-C is a dominant regulator of lymphangio-
genesis in both early and advanced gastric cancer [3,4].
Increased VEGF-C expression had a significant correla-
tion with LVD, LVI and lymph node metastasis [5], but
its prognostic value remained controversial. VEGF-D
was involved in lymphatic spreading of gastric cancer
cells and could be an independent prognostic marker
[6]. VEGFR-3 was also indicated as a prognostic factor
[6]. Another growth factor, VEGF-A, which regulated
angiogenesis, was also considered to stimulate lymphan-
giogenesis by binding to VEGFR-2 recently. Increased
VEGF-A expression level of gastric cancer patients had
been proven to be related with microvessel density
(MVD), hematogenous metastasis, peritoneal dissemina-
teion and poor prognosis. However, it remains unknown
whether both of the intratumoral and peritumoral
lymphtics are stimulated by the three VEGFs secreted
by tumor cells, or whether the I-LVD and P-LVD play
significantly different biological roles in lymph node
metastasis and prognosis in gastric cancer.
Methods
Patients and tumor specimens
Tumor specimens were obtained from 123 patients with
primary gastric cancer who accepted gastrectomy at
Department of Surgery, Tongji Hospital of Tongji Uni-
versity from January 2000 to December 2003. None of
them had received preoperational chemotherapy or
radiotherapy treatment. The study population consisted
of 80 men (65%) and 43 women (35%). The average age
at time of diagnosis was 65 years (ranged from 28 to 87
years). Thirty-one cases of early gastric cancer (EGC)
and 92 cases of advanced gastric cancer (AGC) were
involved in. Histological stage was based on UICC TNM
classification. Other clinical features were summarized
in Table 1. All patients have been followed up clinically
for at least 5 years after surgery. The average follow-up
time was 56 months (ranged from 6 to 85 months). Sur-
vival analysis was performed, including overall survival
(OS), disease-free survival (DFS) and cancer-specific
survival (CSS). OS, DFS and CSS was calculated from
the date of surgery to last contact for living patients, to
t h ed a t eo ft h el a s tf o l l o w - u pf or disease-free patients,
and to the date of gastric-cancer-induced death, respec-
tively. Four EGC cases and 52 AGC cases were occurred
recurrence. Eleven patients had peritoneal dissemina-
tion, 26 patients liver metastasis, and 19 cases relapsed
in the stomach after operation. Forty patients died of
gastric cancer. The current study was approved by the
Research Ethics Committee of Tongji Hospital affiliated
with Tongji University. The normal gastric tissues were
collected as control specimens. All the results were
Table 1 Correlations of LVD with clinicopathological
parameters and VEGFs expressions
Factors N I-LVD P-LVD
mean ±
SD
P mean ± SD P
Tumor
differentiation
0.802 0.739
High
differentiated
11 8.18 ± 2.44 12.07 ± 4.49
Mederately/
poor
differentiated
112 8.00 ± 2.27 12.46 ± 3.60
Tumor size <0.001 <0.001
<3.2 cm 57 8.93 ± 2.34 11.18 ± 3.80
≥ 3.2 cm 66 7.23 ± 1.91 13.50 ± 3.21
Depth of invasion 0.433 0.026
pT1-2 69 8.16 ± 2.51 11.78 ± 3.52
pT3-4 54 7.83 ± 1.96 13.26 ± 3.71
Lymph node
metastasis
0.056* <0.001
Negative 57 8.47 ± 2.27 10.50 ± 3.42
Positive 66 7.65 ± 2.24 13.98 ± 3.10
LVI 0.700 <0.001
Negative 83 8.08 ± 2.33 11.23 ± 3.29
Positive 40 7.91 ± 2.22 14.36 ± 3.44
VI 0.905 <0.001
Negative 86 8.00 ± 2.38 11.65 ± 3.81
Positive 37 8.05 ± 2.67 14.24 ± 2.53
TNM stage 0.067 <0.001
I - II 71 8.34 ± 2.42 11.33 ± 3.29
III - IV 52 7.58 ± 2.01 13.92 ± 3.66
VEGF-A expression 0.527 0.091
Low 44 7.84 ± 2.51 11.68 ± 3.54
High 79 8.26 ± 2.21 12.84 ± 3.69
VEGF-C expression 0.092* 0.003
Low 42 7.55 ± 2.37 11.06 ± 3.26
High 81 8.00 ± 2.34 13.13 ± 3.69
VEGF-D expression 0.514 0.005
Low 72 7.90 ± 2.47 11.65 ± 3.44
High 51 8.18 ± 1.99 13.53 ± 3.73
P, t test; P*, Mann-Whitney U Test. Abbreviation: LVD: lymphatic vessel density;
LVI: lymphatic vessel invasion. VI: venous invasion.
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the means were calculated for each case based on the
data obtained.
Single immunohistochemistry for D2-40, VEGF-A, VEGF-C,
VEGF-D and VEGFR-3
For immunohistichemical staining, 4 μm-thick paraffin-
embedded slides were cut from each study block. Sec-
tions were treated with 0.3% H2O2 for 10 min at room
temperature. For antigen retrieval, the slides were
heated in a microwave oven containing 0.01 mmol/L
sodium citrate (pH 6.0). Slides were incubated at 4°C
overnight in a humidity tray with primary antibodies,
VEGF-A (mouse monoclonal antibody, 1:100, DAKO),
VEGF-C (goat polyclonal antibody, 1:100, Santa Cruz
Biotechnology, Santa Cruz, CA), VEGF-D (goat polyclo-
nal antibody, 1:100, Santa Cruz), VEGFR-3 (goat poly-
clonal antibody, 1:100, Santa Cruz) and D2-40 (mouse
monoclonal antibody, 1:100, DAKO), respectively. Slides
were rinsed thrice in 0.1 mmol/L PBS for 2 min, and
incubated for 30 min at room temperature with goat
anti-rabbit/mouse horseradish peroxidase (Envision,
DAKO, CA) to identify the target. The sections were
developed with 3’ 3-diaminobenzidine. The normal goat
IgG was served as negative reaction control for staining
of VEGF-C, VEGF-D and VEGFR-3, and the normal
rabbit IgG was served as negative reaction control for
staining of VEGF-A and D2-40.
Double immunohistochemical staining for D2-40/CD34
The double immunohistochemical staining for D2-40/
CD34 was further processed to evaluate the specificity
of D2-40 expression in lymphatic endothelium. The pro-
posal was according to the manufacturer’s instruction
(No: 95-9999, Histostain-DS Kit, Zymed, CA). Paraffin-
embedded 4 μm sections were deparaffinized with
xylene and rehydrated. The slides were submerged in
peroxidase quenching solution for 10 min. After being
incubated overnight at 4°C with the primary antibodies
against CD34 (mouse monoclonal antibody, 1:100,
DAKO, Carpinteria, CA), the sections were treated with
serum blocking solution, followed by being incubated
with the biotinylated secondary antibody (DAKO). Sub-
sequently, the alkaline phosphatase conjugate was used
to each section for 10 min. And then, the sections were
treated with the substrate chromogen mixture and dou-
ble staining enhancer. The serum blocking solution was
applied again, the slides were incubated with another
primary antibody against D2-40 (mouse monoclonal
antibody, 1:200, GM36190, Gene Tech Company Lim-
ited, Shanghai, China) for 60 min and the biotinylated
second anti-immunoglobulin (Ig) (DAKO) was treated.
After applying with enzyme conjugate for 10 min, the
slides were incubated with the mixture of substrate
buffer, chromogen solution and 0.6% hydrogen peroxide
for HRP and monitored under a microscope. Tap water
containing 0.05% Tween-20 terminated the reaction. For
negative controls, the sections were stained with a non-
immune serum instead of the same concentration of pri-
mary antibody. The CD34 positive blood vessels showed
the intense red stain, and the D2-40 positive lymphatic
vessels showed the dark purple stain.
Double staining for D2-40/Ki-67
For detecting the proliferative activity of the lymphatic
vessels, the method of double immunostaining for D2-
40/Ki-67 was performed. The D2-40 antibody was used
to stain lymphatic vessels endothelium, together with
Ki-67 (rabbit monoclonal antibody, 1:200, Santa Cruz,
USA) to stain proliferative cells. Ki-67 staining (red) was
developed with alkaline phosphatase-conjugated second-
ary antibody, and then D2-40 staining (brown) was
developed with peroxidase-conjugated secondary anti-
body. Proliferative lymphatic vessels were confirmed by
Ki-67 positively stained nuclei that also had concomitant
positive cytoplasmic staining in D2-40 positive cells. The
rate of double-labeled vessels was determined by count-
ing the nuclei of tumor-associated D2-40-positive vessels
(100 nuclei in each tumor) [7].
Assesment of LVD
Intratumoral LVD (hot spots were located at tumor cen-
ter) and peritumoral LVD (hot spots were located at
periphery tissue within 2 mm of tumor adjacent to the
invasive front) were assessed separately [2,7-9]. Quanti-
tative analysis of lymphatic vessel density was performed
in sections which were single-stained for D2-40. Five
areas with most lymphatics regions ("hot spots”)w e r e
chosen at × 40 magnification by light microscopy. LVD
was assessed by counting all stained vessels at × 200
magnification. The mean number of lymphatics assessed
was determined as LVD. Lymphatic vessel invasion
(LVI) was detected to be present if at least one tumor
cell cluster was in D2-40 positive vessels [10]. Scoring
and counting were performed independently by two
investigators who had no clinical information of the
patients. The mean P-LVD and I-LVD were calculated
for each case.
Assesment of VEGFs and VEGFR-3 expressions
Positive staining of VEGF-A, -C and -D expression was
defined as the previous studies [6,11]. Staining results
for the above three VEGFs were semiquantitatively
assessed by an immunohistochemical score combined
with the percentage of tumor cells showing specific
immunoreactivity. Staining intensity was given with four
grades: none (0), weak (1), moderate (2) and strong (3).
The percentage of positive carcinoma cells was given
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(50% ~ 100%), respectively. The total score was calcu-
lated by multiplying the staining intensity and the per-
centage of positive tumor cells. The median of the score
was selected as the cutoff level according to which
tumors were categorised into low- (0 ~ 3) and high-
expression (4 ~ 6) tumors [6,11]. VEGFR-3-positive ves-
sels were determined as described earlier [12]. The ves-
sels of three hot spots areas were counted at × 400
magnification. Staining was considered as positive when
more than 5% of endothelium showed a staining [6].
Peritumoral VEGFR-3-positive vessels (P-VEGFR-3) and
intratumoral VEGFR-3-positive vessels (I-VEGFR-3)
were assessed as above LVD.
Statistical analysis
Statistical analysis was performed using the Statistics
Package for the Social Science software (version 11.5;
SPSS Inc, Chicago, IL). Specimens were divided into two
categories according to the median values of I-LVD and
P-LVD, respectively. The correlations of I-LVD and P-
LVD with clinicopathologic parameters and VEGFs
expressions were analysed by independent samples t test
or Mann-Whitney U test. The correlations of VEGFR-3
expression with clinical parameters were analysed by
Pearson Chi-Square Tests. The related factors about
lymph node metastasis in gastric cancer were accom-
plished using the multivariant logistic regression analy-
sis. Survival curves were obtained using Kalplan-Meier
method and compared by log-rank test. Multivariate
survival analysis was evaluated using Cox’s proportional
hazard method. All the statistical analysis was two sides
with significance defined as P < 0.05.
Results
Intratumoral and peritumoral lymphatic characteristics in
gastric cancer
The D2-40-positive lymphatic vessels had irregular mor-
phology and thin-walled lumen. Lymphatic vessels in
gastric tissues were mostly located in the layer of sub-
mucosa (Figure 1). The lymphatic vessels (D2-40-posi-
tion) and blood vessels (CD34-position) were clearly
distinguished by further double staining (Figure 2).
Intratumoral lymphatic vessels usually were collapsed,
small and irregular (Figure 3), but some noncollapsed
lymphatics showed open lumen, and occasionally con-
tained invading tumor cells clusters (Figure 4). The
peritumoral lymphatic vessels in the superficial and
deep part of submucosa were all enlarged with the lym-
phatic cavities dilated (Figure 5, Figure 6). The lympha-
tic vessel invasion was observed in 38 cases. No
significant correlation was found between the numbers
of LVD in tumor center and in control tissues (8.02 ±
2.28 vs 8.13 ± 1.04, P > 0.05). However, the numbers of
P-LVD (12.15 ± 3.75) were significantly higher than
that in control tissues and tumor center (P < 0.05). No
statistical differences was found between the two meth-
ods of detecting lymphatics (single staining for D2-40
and double staining for D2-40/CD34) (I-LVD, 8.02 ±
2.28 vs 7.80 ± 2.33; P-LVD, 12.15 ± 3.75 vs 12.42 ±
3.67, P > 0.05).
Correlations of I-LVD and P-LVD with clinicopathologic
parameters and VEGFs expressions
The correlations of I-LVD and P-LVD with clinico-
pathologic parameters were shown in Table 1. Increased
I-LVD was significantly associated with smaller tumor
size (P < 0.001). No correlations was found between
Figure 1 The D2-40-positive lymphantics mainly located at the
layer of submucosa in gastric tissue (arrows). IHC, magnification:
×200.
Figure 2 The double immunohistochemical staining for D2-40
and CD34 clearly distinguished the lymphatic vessels (black
arrow) from blood vessels (red arrow). IHC, magnification: ×400.
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cantly correlated with larger tumor size (P < 0.001),
depth of invasion (P = 0.026), lymph node metastasis (P
< 0.001), LVI (P < 0.001), venous invasion (VI) (P <
0.001), TNM stage (P < 0.001), VEGF-C (P = 0.003) and
VEGF-D expression (P = 0.005).
Expression of the three VEGFs showed a positive cyto-
plasmic staining in gastric cancer cells. High expression
level of VEGF-A (Figure 7), VEGF-C (Figure 8) and
VEGF-D (Figure 9) were observed in 64.2% (79/123),
65.9% (81/123) and 41.5% (51/123) of specimens,
respectively. Neither I-LVD nor P-LVD was found sig-
nificantly associated with VEGF-A expression (P > 0.05).
Proliferative activities in intra- and peritumoral
lymphatics
Proliferative lymphatic vessels were found in the tumor
periphery, (Figure 10). The rate of Ki-67-positive lym-
phatic vessel nuclei in the tumor periphery was (0.81 ±
0.13)%. No proliferative lymphatic vessel was found in
the tumor center (Figure 11). Lymphatics invasion could
be observed in the peritumoral tissues (Figure 12).
VEGFR-3 expression in lymphatic vessels
The VEGFR-3-positive expression in tumor periphery
(P-VEGFR-3) was found in 55 of the 123 cases, occa-
sionally with cancer cell clusters invading (Figure 13).
However, only 34 of 123 cases had a VEGFR-3-positive
expression at the tumor center (I-VEGFR-3) (Figure 14).
Figure 3 The intratumoral lymphatic vessels in gastric cancer
were collapsed (arrow); Double immunohistochemical staining,
magnification: ×200.
Figure 4 The invading cancer cells cluster were present in
lymphatic vessel invasion (LVI). Double immunohistochemical
staining for D2-40/CD34, magnification: ×400.
Figure 5 The peritumoral lymphatic vessels in gastric cancer
were enlarged with dilated lumen located at the superficial
submucosa. IHC, magnification: ×200.
Figure 6 The peritumoral lymphatic vessels in gastric cancer
were enlarged with dilated lumen located at deep part of
submucosa. IHC, magnification: ×200.
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and contained no or few RBCs.
In peripheral tumor tissues, VEGFR-3 expressions
were significantly correlated rather with VEGF-C high
expression (P < 0.000), VEGF-D high expression (P =
0.043), increased P-LVD (P < 0.001) and the presence of
LVI (P = 0.003), than with VEGF-A expression,
increased I-LVD, venous invasion and lymph node
metastasis (P > 0.05). No correlations were observed
between I-VEGFR-3 expression and clinical parameters
(P > 0.05). (Table 2)
Predictive value of LVD for lymph node metastasis
A sar e s u l to fm u l t i v a r i a t el o g i s t i cr e g r e s s i o na n a l y s i s
in Table 3, VEGF-C expression and P-LVD were
significantly asscoiated with lymph node metastasis (P =
0.024, P = 0.045, respectively). I-LVD, VEGF-A, VEGF-
D and P-VEGFR-3 expression did not show the predic-
tive value for lymph node metastasis in gastric cancer.
(Table 3)
Prognostic significance of I-LVD and P-LVD
On univariate survival analysis, P-LVD was associated
with poor overall survival (Figure 15, P <0 . 0 0 1 ) ,d i s -
ease-free survival (Figure 16, P < 0.001) and cancer-spe-
cific survival (Figure 17, P < 0.001). However, I-LVD
was correlated with a nonsignificantly trend towards all
the above respectively (overall survival, P = 0.5835,
Figure 18; disease-free survival, P = 0.2844, Figure 19;
cancer-specific survival, P = 0.6246, Figure 20).
Figure 7 VEGF-A expression in the cytoplasm in gastric cancer.
IHC, magnification: ×400.
Figure 8 VEGF-C expression in the cytoplasm in gastric cancer.
IHC, magnification: ×400.
Figure 9 VEGF-D expression in the cytoplasm in gastric cancer.
IHC, magnification: ×200.
Figure 10 Ki-67-positive lymphatic vessel nuclei (arrows) were
detected in the tumor periphery. Double staining for D2-40/Ki-67,
magnification: ×400.
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LVD could be an independent prognostic factor for
both overall survival (P = 0.045) and disease-free survi-
val (P = 0.031), despite cancer-specific survival. More-
over, presence of LVI and TNM stage could serve as the
independent predictors for all the three survivals (LVI, P
= 0.040, 0.043, 0.039; TNM stage, P = 0.048, 0.001,
0.001, Table 4). VEGF-A expression was the indepen-
dent prognostic predictor only for overall survival (P =
0.033). No statistically significant correlations for I-LVD,
VEGF-C, VEGF-D and P-VEGFR-3 with any of the sur-
vivals were found. (Table 4)
Discussion
Recently, the D2-40 antibody, a new marker for lympha-
tic endothelium, was identified as the specific antibody
against human podoplanin [13]. Many studies have
indicated the immunostaining of D2-40 is specific for
evaluation of lymphatic invasion and lymphatic micro-
vessel density in human cancers, including in gastric
cancer [14-17]. In this study, LVD and lymphatic vessel
invasion were identified by D2-40 staining, and con-
firmed by double staining for D2-40 and CD34, which
clearly discriminated lymphatics from blood vessels
further. Our results also showed the numbers of lym-
phatic vessel density evaluated by the two methods had
no statistical significance. That meant the D2-40 was
specific for lymphatic endothelium in gastric cancer.
Similar to the precious reports, the D2-40-positive lym-
phatic vessels in our study usually had the irregular
shape and thin-walled lumen containing no RBCs.
Figure 11 No Ki-67 positive expression in the intratumoral
lymphatics nuclei. Double staining for D2-40/Ki-67, magnification:
×400.
Figure 12 Lymphatic vessels invasion was detected in the
peritumoral tissue (arrows). Double staining for D2-40/Ki-67,
magnification: ×400.
Figure 13 The VEGFR-3-positive expression in the endothelial
cells cytoplasm in tumor periphery (P-VEGFR-3), occasionally
with cancer cell clusters invading (arrows). IHC, magnification:
×400.
Figure 14 The VEGFR-3-positive expressions were located at
tumor center (arrows). IHC, magnification: ×200.
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observed here. The ITLs mostly were collapsed, small
and had less numbers than PTLs, which had obviously
increased numbers with dilated lumen. The larger
tumor size was, the less the numbers of I-LVD were.
This result was in agreement with other report in
advanced gastric cancer [2]. Its reason was postulated as
that the lymphatics in the tumor tissue were destroyed
by invaded tumor cells, or high interstitial fluid pressure
caused by expanding tumor cell masses and growing
malignant cells in a confined space [18]. Although some
noncollapsed intratumoral lymphatics had open lumen
and occasionally contained invading tumor cells, our
results didn’t show the linkage of I-LVD with lymphatic
invasion and lymph node metastasis. However, Peng
Gao et al. indicated I-LVD was correlated with LVI and
lymph node metastasis in early gastric cancer [2]. In this
study, while despite that I-LVD had a trend of correla-
tion with LNM, no statistical significance was found
(P = 0.056). Except for the above, few studies about I-
LVD in gastric cancer were reported.
The significant association of ITLs with LNM was
observed in other human tumors, paplillary thyroid car-
cinoma [19], for instant. The increased I-LVD was cor-
related with neck node metastasis in oropharyngeal
Table 2 Correlations of VEGFR-3 expression at differenr
tumor location with clinical parameters
Factors N I-VEGFR-3 P-VEGFR-3
N (%) P N (%) P
VEGF-A expression 0.107 0.067
Low 44 16(36.36) 15(34.09)
High 79 18(22.78) 40(50.63)
VEGF-C expression 0.795 < 0.001
Low 42 11(26.19) 9 (21.43)
High 81 23(28.40) 46(56.79)
VEGF-D expression 0.968 0.043
Low 72 20(27.78) 27(37.50)
High 51 14(27.45) 28(54.90)
P-LVD 0.813 <0.001
<14 60 16(26.67) 10(16.67)
≥ 14 63 18(28.57) 45(71.43)
I-LVD 0.412 0.153
<8 58 14(24.14) 22(37.93)
≥ 8 65 20(30.77) 33(50.77)
Lymph node metastasis 0.934 0.190
Negative 55 19(34.55) 21(38.18)
Positive 68 15(22.06) 34(50.00)
LVI 0.681 0.003
Negative 76 22(28.95) 26(34.21)
Positive 47 12(25.53) 29(61.70)
VI 0.387 0.448
Negative 87 26(29.89) 37(42.53)
Positive 36 8 (22.22) 18(50.00)
Abbreviation: LVD: lymphatic vessel density; LVI: lymphatic vessel invasion; VI:
venous invasion; I-VEGFR-3: VEGFR-3 positive expression in the tumor center;
P-VEGFR-3: VEGFR-3 positive expression at the tumor periphery.
Table 3 Multivariate logistic regression analysis for
lymph node metastasis
Factors Odds ratio 95% CI P
P-LVD 3.548 1.030 -12.226 0.045
I-LVD 1.300 0.964 - 1.754 0.085
VEGF-A 0.510 0.138 - 1.884 0.313
VEGF-C 4.069 1.198 - 13.820 0.024
VEGF-D 3.162 0.834 - 11.992 0.091
P-VEGFR-3 2.919 0.747 - 11.403 0.123
Abbreviation: LVD: lymphatic vessel density; P-VEGFR-3: VEGFR-3 positive
expression at the tumor periphery.
Figure 15 Relationship between P-LVD with overall survival (P
< 0.001).
Figure 16 Relationship between P-LVD with disease-free
survival (P < 0.001).
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in pancreatic endocrine tumors [21]. Wherever the lym-
phangiogenesis occurs in peritumoral and intratumoral
tissues, the association of it with regional LNM is
mainly dependent on whether the new-formed lympha-
tics are functional, or not [18]. The function of LECs
was measured by Ki-67 expression in the nuclei, how-
ever, we didn’t observe the proliferative activity in ITLs
endothelium. Furthermore, correlation wasn’to b s e v e d
between I-LVD and VEGF-A ,V E G F - C ,V E G F - Da n d
VEGFR-3 expression level in the intratumoral tissues.
Therefore, ITLs in gastric cancer were unfunctional
according to our results. Although tumor-secreted
V E G F - C / - Da n d ,e v e nV E G F - At oal e s s e re x t e n t ,a r e
important for inducing intratumoral lymphangiogenesis
in solid tumor mass [22], our results demontrated that
ITLs in gastric cancer didn’t be stimulated by VEGF-C/-
D-mediated VEGFR-3 signaling pathway or VEGF-A
expression. Similar to our observations, no relationships
were found between ITLs proliferation and VEGF-C/
VEGFR-3 expression in head and neck cancer and cuta-
neous melanoma [9,20]. However, I-LVD was correlated
with VEGF-C expression in pancreatic endocrine tumors
[21].
In contrast to ITLs and I-LVD in the present study,
the PTLs endothelium showed the proliferative activity
with Ki-67 expression on D2-40-positive lymphatics,
and increased P-LVD was correlated with LVI and
LNM. Our results demonstrated that PTLs were func-
tional in gastric cancer, and the dilated PTLs increased
Figure 17 Relationship between P-LVD with cancer-specific
survival (P < 0.001).
Figure 18 Relationship between I-LVD with overall survival
(P = 0.5825).
Figure 19 Relationship between I-LVD with disease-free
survival (P = 0.2844).
Figure 20 Relationship between I-LVD with cancer-specific
survival (P = 0.6246).
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Page 9 of 11drainage activity in the tumor periphery. Furthermore,
positive correlations were observed between P-LVD
and VEGF-C, VEGF-D and VEGFR-3 expression in the
tumor periphery (P-VEGFR-3), which meant VEGF-C
and VEGF-D induced the peritumoral lymphangiogen-
esis via stimulating VEGFR-3 expression on LECs. Our
observation also showed the closely relationships
between P-VEGFR-3 and VEGF-C/VEGF-D expression.
The increased number of functional and draining PTLs
with dilated lumen may collect more metastatic cancer
cells from the tumor surface, and then facilitate lym-
phatics invasion and metastasis [23]. Our results were
in agreement with the findings in cutaneous mela-
noma, squamous cell carcinomas of the head and neck,
and gastric cancer investigated by other authors
[1,5,9,10,24-26]. VEGF-A expression was not correlated
with P-LVD and I-LVD in this study. Even demon-
strated in xenograft fibrosarcomas, VEGF-A has
induced PTL growth in avascular cormea and pro-
moted lymph node metastasis via VEGF-C/-D/VEGFR-
3-independent pathway [27], its role on lymphangio-
genesis remains undetermined in human tumors. In
g a s t r i cc a n c e r ,V E G F - Aa n dV E G F - Cm a yp l a yt h ed i s -
tinct role: VEGF-A is more likely to be associated with
haematogenous metastasis, while VEGF-C is indictive
of lymphatic metastasis [28].Other report showed the
increased expression of VEGF-A as well as VEGF-C
expression is essential in lymph node metastasis [29].
VEGF-A stimulates the tumor angiogenesis through
activation of VEGFR-1 and VEGFR-2. However, its
mechanism of inducing lymphangiogenesis and the
function of lymphantics it induced need further
studied.
In early gastric cancer, P-LVD and I-LVD could be
risk factors for lymph node metastasis [1]. Our results
indicated that only P-LVD was the predictor for lymph
node metastasis in gastric cancer, but not I-LVD. Addi-
tionally, increased P-LVD was associated with worse dis-
ease-free survival and overall survival, but not with
cancer-specific survival. No correlations were found
between I-LVD and patients’ prognosis in this study.
Multivariate analysis indicated increased P-LVD could
be the prognostic factors for disease-free survival and
overall survival in gastric cancer, and as an independent
predictor for lymph node metastasis. Our results were
similar with some other studies. Increased peritumoral
lymphangiogenesis may be an indicator of risk of LNM
in patients with head and neck squamous cell carcinoma
[26]. However, in cutaneous melanoma, increased P-
LVD was significantly correlated with improved patient
survival, while decreased P-LVD became the predictor
of poor prognosis [9]. Since most solid tumors metasta-
size via lymphatic invasion, LNM becomes an important
prognostic factor for the patients’ outcome [18], our
results also showed that LNM and LVI were the prog-
nostic factors for disease-free survival and overall survi-
val in gastric cancer, and LVI was associated with
cancer-specific survival further. Only VEGF-A expres-
sion had the significant correlation with overall survival.
VEGF-C was another independent risk factor for LNM.
The roles of P-LVD and I-LVD in human tumors exist
differently. It may be due to the various biological beha-
viors of tumor cells in different types of human tumors,
or the differences in patient selection, experimental
design and analytic method.
Conclusions
Our results suggested PTLs, rather than ITLs, are func-
tional in gastric cancer. Increased P-LVD has the corre-
lation with VEGF-C/-D/VEGFR-3 system, and could be
as the independent risk factor for lymph node metastasis
and prognostic factor in gastric cancer.
Table 4 Cox regression analysis of independent factors affecting disease-free survival, cancer-specific survival and
overall survival
Factors Cancer-Specific Survival Disease-Free Survival Overall Survival
OR (95% CI) P OR (95% CI) P OR (95% CI) P
P-LVD 2.099(0.91-4.87) 0.084 2.418(1.08-5.40) 0.031 2.895 (1.02-8.19) 0.045
I-LVD 1.205(0.56-2.63) 0.639 1.325(0.62-2.85) 0.472 1.959 (0.90-4.24) 0.088
VEGF-A 1.386(0.50-3.83) 0.528 1.364(0.67-2.78) 0.391 2.437(1.10-5.45) 0.030
VEGF-C 2.423(0.89-6.63) 0.085 1.630(0.77-3.47) 0.205 1.562 (0.79-3.34) 0.182
VEGF-D 0.511(0.19-1.36) 0.178 1.916(0.90-4.10) 0.094 1.621 (0.81-3.98) 0.190
LVI 2.716 (1.05-7.04) 0.040 2.477(1.03-5.97) 0.043 2.578 (1.05-6.34) 0.039
LNM 2.115(0.68-6.60) 0.197 2.428(1.18-5.02) 0.017 3.426 (1.66-7.06) 0.001
VI 2.943(0.89-9.77) 0.078 1.697(0.75-3.87) 0.208 1.477(0.63-3.48) 0.373
P-VEGFR-3 1. 499(0.98-2.31) 0.067 1.099(0.53-2.28) 0.800 1.402 (0.68-2.90) 0.361
TNM stage 1.523(1.00-2.31) 0.048 1.674(1.25-2.25) 0.001 1.656(1.23-2.23) 0.001
Abbreviation: P-LVD: peritumoral lymphatic vessel density; I-LVD: intratumoral lymphatic vessel density; LVI: lymphatic vessel invasion; LNM: lymph node
metastasis; VI: venous invasion; P-VEGFR-3: VEGFR-3 positive expression at the tumor periphery.
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